Printer Friendly

LECTEC BOARD APPROVES ADDED EMPHASIS ON TRANSDERMAL BUSINESS DEVELOPMENT; CITES SIGNIFICANT OPPORTUNITIES

 LECTEC BOARD APPROVES ADDED EMPHASIS ON TRANSDERMAL BUSINESS
 DEVELOPMENT; CITES SIGNIFICANT OPPORTUNITIES
 MINNETONKA, Minn., Nov. 27 /PRNewswire/ -- LecTec Corporation (NASDAQ: LECT) today announced an acceleration of activities to develop new transdermal (through the skin) drug delivery products. The decision to more aggressively fund this segment of the company was unanimously agreed by the board of directors at the conclusion of LecTec's annual meeting.
 Dr. Tom Brunelle, senior vice president, reported to the board on the status of ethical and over-the-counter (OTC) transdermal drug projects. The current areas of business development focus include dermatological, analgesic, antibiotic, and oncological products. Collaborators for these projects include pharmaceutical companies and leading research universities in North America and Europe.
 "We have been aggressively pursuing product development agreements and marketing partners for several exciting and needed drug products. In addition to products that will treat conditions affecting the skin, we are also working on the delivery of medications to enhance the quality of life for cancer victims, reduce or eliminate the craving for nicotine and provide new means to apply over-the-counter medications and cosmetics to the body."
 In other matters covered by the LecTec board, President and CEO George B. Ingbrand reported on the company's revenue and earnings growth, manufacturing capacity expansion and previewed new product introductions for the company's medical tape group. Sales of the company's core business, medical electrodes and conductive adhesives, remains strong and is projected to strengthen with the addition of a new product line during the fiscal year.
 LecTec Corporation is a medical products development and manufacturing company. LecTec's products include cardiac diagnostic and monitoring electrodes, nerve and muscle stimulation electrodes, medical tapes and transdermal drug delivery systems. The company's headquarters and research center are located in Minnetonka, Minn., with a manufacturing center in Edina, Minn. LecTec is traded on NASDAQ under the symbol LECT.
 -0- 11/27/91
 /CONTACT: Jan Jachimowic of LecTec Corporation, 612-933-2291/
 (LECT) CO: LecTec Corporation ST: Minnesota IN: MTC SU:


AL-DS -- MN005 -- 7689 11/27/91 10:54 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 27, 1991
Words:333
Previous Article:CITIZENS FEDERAL EXTENDS STOCK OFFERING DEADLINE
Next Article:/C O R R E C T I O N -- THE IKEA $10 CHRISTMAS TREE/
Topics:


Related Articles
LECTEC REVIEWING POSSIBLE PATENT INFRINGEMENTS OF TRANSDERMAL NICOTINE TECHNOLOGY
UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
LECTEC BOARD INTENSIFIES FUNDING FOR TRANSDERMAL PATCH DEVELOPMENT; TO TREAT SMOKERS, CANCER PATIENTS, OTHERS
LECTEC TO LAUNCH NEW PRODUCT FOR TREATMENT OF BED SORES AND OTHER CHRONIC WOUNDS
LECTEC AND UNIVERSITY OF MINNESOTA PURSUE SAFER ALTERNATIVE TO NICOTINE FOR SMOKING CESSATION PATCHES
TECHNICAL CHEMICALS AND PRODUCTS, INC. ANNOUNCES THE SIGNING OF A LETTER OF INTENT WITH PHARMA PATCH PLC
Sano Provides Update on Clinical Trial Programs for its Lead Products
MacroChem Announces Stock Repurchase Program Board Approves Repurchase of Up to One Million Common Shares
LAM Pharmaceutical CEO Interviewed by Wall Street Reporter.
LAM Pharmaceutical and Ixora Bio Medical Announce The Launch of Ixora's First Product.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters